Cargando…
Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction
Leukocytosis is a common finding in patients with ST elevation myocardial infarction (STEMI) and portends a poor prognosis. Interleukin 1-β regulates leukopoiesis and pre-clinical studies suggest that anakinra (recombinant human interleukin-1 [IL-1] receptor antagonist) suppresses leukocytosis in my...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786840/ https://www.ncbi.nlm.nih.gov/pubmed/35075216 http://dx.doi.org/10.1038/s41598-022-05374-w |
_version_ | 1784639206426935296 |
---|---|
author | Del Buono, Marco Giuseppe Damonte, Juan Ignacio Trankle, Cory R. Kadariya, Dinesh Carbone, Salvatore Thomas, Georgia Turlington, Jeremy Markley, Roshanak Canada, Justin M. Biondi‐Zoccai, Giuseppe G. Kontos, Michael C. Van Tassell, Benjamin W. Abbate, Antonio |
author_facet | Del Buono, Marco Giuseppe Damonte, Juan Ignacio Trankle, Cory R. Kadariya, Dinesh Carbone, Salvatore Thomas, Georgia Turlington, Jeremy Markley, Roshanak Canada, Justin M. Biondi‐Zoccai, Giuseppe G. Kontos, Michael C. Van Tassell, Benjamin W. Abbate, Antonio |
author_sort | Del Buono, Marco Giuseppe |
collection | PubMed |
description | Leukocytosis is a common finding in patients with ST elevation myocardial infarction (STEMI) and portends a poor prognosis. Interleukin 1-β regulates leukopoiesis and pre-clinical studies suggest that anakinra (recombinant human interleukin-1 [IL-1] receptor antagonist) suppresses leukocytosis in myocardial infarction. However, the effect of IL-1 blockade with anakinra on leukocyte count in patients with STEMI is unknown. We reviewed the white blood cell (WBC) and differential count of 99 patients enrolled in a clinical trial of anakinra (n = 64) versus placebo (n = 35) for 14 days after STEMI. A complete blood cell count with differential count were obtained at admission, and after 72 h, 14 days and 3 months. After 72 h from treatment, anakinra compared to placebo led to a statistically significant greater percent reduction in total WBC count (− 35% [− 48 to − 24] vs. − 21% [− 34 to − 10], P = 0.008), absolute neutrophil count (− 48% [− 60 to − 22] vs. − 27% [− 46 to − 5], P = 0.004) and to an increase in absolute eosinophil count (+ 50% [0 to + 100] vs. 0% [− 50 to + 62], P = 0.022). These changes persisted while on treatment at 14 days and were no longer apparent at 3 months after treatment discontinuation. We found that in patients with STEMI IL-1 blockade with anakinra accelerates resolution of leukocytosis and neutrophilia. This modulation may represent one of the mechanisms by which IL-1 blockade improves clinical outcomes. |
format | Online Article Text |
id | pubmed-8786840 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-87868402022-01-25 Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction Del Buono, Marco Giuseppe Damonte, Juan Ignacio Trankle, Cory R. Kadariya, Dinesh Carbone, Salvatore Thomas, Georgia Turlington, Jeremy Markley, Roshanak Canada, Justin M. Biondi‐Zoccai, Giuseppe G. Kontos, Michael C. Van Tassell, Benjamin W. Abbate, Antonio Sci Rep Article Leukocytosis is a common finding in patients with ST elevation myocardial infarction (STEMI) and portends a poor prognosis. Interleukin 1-β regulates leukopoiesis and pre-clinical studies suggest that anakinra (recombinant human interleukin-1 [IL-1] receptor antagonist) suppresses leukocytosis in myocardial infarction. However, the effect of IL-1 blockade with anakinra on leukocyte count in patients with STEMI is unknown. We reviewed the white blood cell (WBC) and differential count of 99 patients enrolled in a clinical trial of anakinra (n = 64) versus placebo (n = 35) for 14 days after STEMI. A complete blood cell count with differential count were obtained at admission, and after 72 h, 14 days and 3 months. After 72 h from treatment, anakinra compared to placebo led to a statistically significant greater percent reduction in total WBC count (− 35% [− 48 to − 24] vs. − 21% [− 34 to − 10], P = 0.008), absolute neutrophil count (− 48% [− 60 to − 22] vs. − 27% [− 46 to − 5], P = 0.004) and to an increase in absolute eosinophil count (+ 50% [0 to + 100] vs. 0% [− 50 to + 62], P = 0.022). These changes persisted while on treatment at 14 days and were no longer apparent at 3 months after treatment discontinuation. We found that in patients with STEMI IL-1 blockade with anakinra accelerates resolution of leukocytosis and neutrophilia. This modulation may represent one of the mechanisms by which IL-1 blockade improves clinical outcomes. Nature Publishing Group UK 2022-01-24 /pmc/articles/PMC8786840/ /pubmed/35075216 http://dx.doi.org/10.1038/s41598-022-05374-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Del Buono, Marco Giuseppe Damonte, Juan Ignacio Trankle, Cory R. Kadariya, Dinesh Carbone, Salvatore Thomas, Georgia Turlington, Jeremy Markley, Roshanak Canada, Justin M. Biondi‐Zoccai, Giuseppe G. Kontos, Michael C. Van Tassell, Benjamin W. Abbate, Antonio Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction |
title | Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction |
title_full | Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction |
title_fullStr | Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction |
title_full_unstemmed | Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction |
title_short | Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction |
title_sort | effect of interleukin-1 blockade with anakinra on leukocyte count in patients with st-segment elevation acute myocardial infarction |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786840/ https://www.ncbi.nlm.nih.gov/pubmed/35075216 http://dx.doi.org/10.1038/s41598-022-05374-w |
work_keys_str_mv | AT delbuonomarcogiuseppe effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction AT damontejuanignacio effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction AT tranklecoryr effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction AT kadariyadinesh effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction AT carbonesalvatore effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction AT thomasgeorgia effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction AT turlingtonjeremy effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction AT markleyroshanak effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction AT canadajustinm effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction AT biondizoccaigiuseppeg effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction AT kontosmichaelc effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction AT vantassellbenjaminw effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction AT abbateantonio effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction |